{"filings":[{"id":1730357,"accession_number":"0001193125-26-308343","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2026-07-20T11:35:14+00:00","items":["8.01"],"status":"ready","headline":"FDA accepts Dyne's BLA for DYNE-251 in DMD exon 51 skipping; Priority Review granted","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted BLA for z-rostudirsen (DYNE-251) to treat Duchenne muscular dystrophy amenable to exon 51 skipping.","Priority Review assigned; PDUFA target action date is January 21, 2027.","Company expects potential U.S. launch in Q1 2027 if approved on anticipated timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-20","daily_digest_url":"/daily/2026-07-20","daily_digest_rank":5},{"id":1195202,"accession_number":"0001818794-26-000005","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2026-06-22T20:15:29+00:00","items":["5.02"],"status":"ready","headline":"Barry E. Greene elected to Dyne Therapeutics board; receives option for 57,463 shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elected as Class I director effective June 22, 2026, to serve until 2027 annual meeting.","Received option for 57,463 shares at $20.87 per share, vesting monthly over 3 years.","Will receive $45,000 annual cash retainer and standard equity grants per non-employee director program.","No committee appointments; board determined independent per Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1093316,"accession_number":"0001818794-26-000003","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2026-06-17T11:35:15+00:00","items":["1.01","2.03"],"status":"ready","headline":"Dyne Therapeutics expands Hercules debt facility to $400M, borrows $50M on June 16, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Expanded loan facility to aggregate $400M with two new $50M tranches and increased final tranche by $25M.","Borrowed $50M on closing; outstanding principal now $200M; up to $200M additional available ($125M milestone-based, $75M discretionary).","Minimum cash covenant reduced to 40% of outstanding obligations (from 60%), tested only if market cap < $1.65B; testing starts July 1, 2027.","Interest rate: WSJ prime + 2.45% (floor 7.50%); interest-only period through July 1, 2029, extendable to maturity.","Maturity date July 1, 2030; first-priority security interest on substantially all assets including IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":918076,"accession_number":"0001193125-26-261696","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2026-06-08T20:05:15+00:00","items":["5.07"],"status":"ready","headline":"Dyne Therapeutics shareholders approve doubling of authorized shares to 400M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected David Lubner, Brian Posner, Jason Rhodes as Class III directors to three-year terms.","Non-binding advisory vote approved executive compensation with ~98% of votes cast in favor.","Authorized common stock doubled from 200M to 400M shares via charter amendment filed June 8.","Charter amended to include officer exculpation provision limiting personal liability.","Deloitte & Touche ratified as independent auditor for fiscal year ending December 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":815676,"accession_number":"0001193125-26-254597","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2026-06-03T11:35:14+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics completes enrollment of ACHIEVE registrational cohort with 71 DM1 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registrational expansion cohort (REC) enrolled 71 participants; topline data expected Q1 2027.","Potential BLA submission for U.S. Accelerated Approval in Q3 2027 using REC and MAD/LTE data.","Potential U.S. launch of z-basivarsen in H1 2028 if FDA grants Priority Review.","Also pursuing approval pathways outside U.S. for DM1 therapy.","ACHIEVE primary endpoint: change in middle finger myotonia via vHOT at 6 months vs placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95755,"accession_number":"0001193125-26-215720","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Q1 net loss $120.9M; BLA for z-rostudirsen on track for Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $120.9M ($0.73 per share) vs $115.4M ($1.05) in Q1 2025.","Cash and marketable securities $972.2M; expected to fund operations into Q1 2028.","R&D expenses $100.9M (down from $106.4M); G&A $24.4M (up from $15.9M) due to launch prep.","Positive pre-BLA meeting with FDA; BLA submission for z-rostudirsen in exon 51 DMD on track for Q2 2026.","ACHIEVE trial enrollment target of 60 participants reached; Phase 3 HARMONIA trial for z-basivarsen in DM1 initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109043,"accession_number":"0001193125-26-084207","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne posts FY2025 net loss $446M; z-rostudirsen BLA submission on track for Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $446.2M ($3.47/share) for FY2025 vs $317.4M ($3.37/share) in FY2024; R&D expense $398.3M.","Cash $1.1B at Dec 31, 2025; expected runway into Q1 2028.","Z-rostudirsen in DMD met primary endpoint: dystrophin 5.46% of normal (p<0.0001); BLA submission planned Q2 2026.","Z-basivarsen in DM1: enrollment completion of registrational cohort expected Q2 2026; topline data Q1 2027.","Advancing four DMD exon-skipping candidates (exons 53, 45, 44, 55) into IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109042,"accession_number":"0001193125-26-009782","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dyne Therapeutics reports preliminary cash of ~$1.1B as of Dec 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities of approximately $1.1 billion as of December 31, 2025.","Figure is a management estimate subject to completion of financial closing procedures; no audit or review by independent accountants.","Company also presented at J.P. Morgan Healthcare Conference on January 12, 2026; presentation content was not detailed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125508,"accession_number":"0001193125-25-329511","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dyne Therapeutics elects Vikram Karnani as Class II director effective Dec 22, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vikram Karnani elected to the Board as an independent director; term expires at 2028 Annual Meeting.","Received option to purchase 59,665 shares at $20.78/share, vesting monthly over three years.","Will receive annual cash compensation of $45,000 plus standard equity grants under non-employee director plan.","No family relationships or material transactions with the Company; standard indemnification agreement entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125507,"accession_number":"0001193125-25-314249","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics prices upsized $350M public offering at $18.44/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 18,980,478 shares at $18.44/share; gross proceeds $350M.","Underwriters granted 30-day option for additional 2,847,071 shares.","Net proceeds estimated at ~$328.5M ($377.9M if option exercised).","Also borrowed $50M second tranche under Hercules Loan Agreement.","Cash runway extended into Q1 2028 with combined resources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125506,"accession_number":"0001193125-25-311221","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["2.03","1.01"],"status":"ready","headline":"Dyne Therapeutics borrows $50M under amended Hercules loan; up to $125M additional available","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $50M second tranche under amended Loan and Security Agreement with Hercules Capital.","Two additional tranches of up to $75M available upon achieving clinical, regulatory, and commercial milestones.","Final tranche of up to $50M subject to Lenders' investment committee approval.","Maturity July 1, 2030; interest at WSJ Prime + 2.45% (floor 7.50%); interest-only until July 2028.","Collateral includes first-priority security interest in substantially all assets, including IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125505,"accession_number":"0001193125-25-310516","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics: DELIVER trial meets primary endpoint; dystrophin 5.46% of normal; BLA submission Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: muscle content-adjusted dystrophin expression 5.46% of normal (p<0.0001), replicating 7-fold increase from MAD portion.","Functional improvement across all six prespecified endpoints; two (TTR Velocity, 10MWR) nominal p<0.05; lung function preserved vs placebo decline.","Long-term data up to 24 months show sustained functional improvement across all assessed endpoints (TTR Velocity, 10MWR, NSAA, SV95C, PUL2.0, FVC%p).","Safety favorable: 1,441 doses administered; 113 patient-years; no related serious TEAEs in REC; two related serious TEAEs in OLE/LTE resolved.","BLA for U.S. Accelerated Approval planned Q2 2026; global Phase 3 initiation Q2 2026; potential U.S. launch Q1 2027 assuming Priority Review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125504,"accession_number":"0001193125-25-266979","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics Q3 net loss $108M; DMD topline data expected Dec 2025; DM1 enrollment delayed to early Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $108.0M ($0.76/share) vs $97.1M ($0.96/share) in Q3 2024; R&D $97.2M, G&A $16.7M.","Cash $791.9M; reaffirms runway into Q3 2027 covering first commercial launch and BLA submissions.","Topline data from DELIVER REC (z-rostudirsen in DMD) on track for Dec 2025; BLA submission Q2 2026, launch Q1 2027.","ACHIEVE REC enrollment (z-basivarsen in DM1) now expected early Q2 2026 (shift from Q4 2025) due to US site activation.","FDA granted Breakthrough Therapy Designation for z-rostudirsen in Aug 2025; one-year DM1 data presented at WMS."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125503,"accession_number":"0001193125-25-228317","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dyne Therapeutics elects Brian Posner as Class III director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Posner elected to Board effective Oct 1, 2025; term runs until 2026 annual meeting.","Posner deemed independent under Nasdaq rules; no committee appointments.","Received option to purchase 70,000 shares at $12.50 strike, vesting monthly over three years.","Annual cash compensation of $45,000 plus standard equity grants under director program.","No family relationships or transactions with company officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142246,"accession_number":"0000950170-25-101620","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne MD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation to DYNE-251 for DMD amenable to exon 51 skipping.","Designation based on DELIVER trial data showing sustained functional improvement over 18 months.","DYNE-251 now joins DYNE-101 (DM1) as Dyne's second compound to receive this designation.","Registrational expansion cohort data expected late 2025; BLA submission for accelerated approval anticipated early 2026.","Benefits include rolling review, Priority Review eligibility, and enhanced FDA support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142245,"accession_number":"0000950170-25-099184","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Q2 net loss $110.9M extends cash runway into Q3 2027 on $215M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $110.9M ($0.97/sh) vs $65.1M ($0.70) in Q2 2024; R&D expenses $99.2M.","Cash $683.9M; July offering net $215.2M; Hercules $100M initial loan; runway into Q3 2027.","DYNE-251 DMD registrational cohort enrolled (32 pts); data late 2025; potential BLA early 2026.","DYNE-101 DM1 FDA Breakthrough Therapy; 60-pt cohort enrollment Q4 2025; data mid-2026; BLA late 2026.","Hercules $275M senior secured loan; 5 tranches; milestones-based drawdown; final tranche subject to approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142244,"accession_number":"0001193125-25-154057","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics prices $200M public offering of 24.2M shares at $8.25/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $200M; net proceeds ~$187M ($215.2M if underwriters exercise 30-day option for 3.6M additional shares).","Closing expected July 2, 2025; all shares sold by the company, resulting in dilution.","Cash runway extended into Q3 2027 inclusive of June 2025 $100M term loan from Hercules Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160258,"accession_number":"0001193125-25-152652","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Dyne Therapeutics enters $275M loan agreement with Hercules Capital; $100M funded immediately","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial tranche of $100M funded on June 27, 2025; additional tranches up to $175M available upon milestones and lender discretion.","Interest rate of WSJ Prime + 2.45% (floor 7.50%); maturity July 1, 2030; interest-only until July 1, 2028, extendable.","First-priority security interest on substantially all assets including IP; covenants include minimum cash and minimum net product revenue post-approval of DYNE-101 or DYNE-251.","Prepayment penalty ranges from 0.75% to 2.0% of prepaid amount; end-of-term charge of 5.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160257,"accession_number":"0001193125-25-141739","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA Breakthrough Therapy Designation for DYNE-101 in DM1; revised Accelerated Approval path","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation to DYNE-101 for myotonic dystrophy type 1 (DM1).","Revised ACHIEVE trial protocol submitted with vHOT as primary endpoint (60 patients, 3:1 randomization).","Enrollment in Registrational Expansion Cohort expected to complete Q4 2025; data mid-2026, submission late 2026.","New 12-month data: sustained vHOT improvement of 3.3 sec at 6 months; QMT strength improved 10% at 6 mo, 20% at 12 mo.","Cash $677.5M as of March 31, 2025; runway extended into Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160256,"accession_number":"0000950170-25-082317","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Dyne Therapeutics shareholders elect Hurwitz, Kersten; approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Edward Hurwitz elected with 62.9M votes for, 27.4M withheld; Dirk Kersten with 58.3M for, 32.0M withheld.","Non-binding advisory say-on-pay approved: 74.4M for, 15.8M against, 81.6K abstain.","Stockholders recommend advisory vote on executive compensation every year (90.2M votes); company will hold annual say-on-pay.","Ratification of Deloitte & Touche LLP as independent auditor for FY2025: 105.6M for, 19.8K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160255,"accession_number":"0000950170-25-066396","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Q1 net loss $115.4M ($1.05/sh); advances DM1 & DMD toward 2026-2027 approvals","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $677.5M; expects funding operations into H2 2026.","R&D expenses $106.4M (Q1 2025) vs $44.5M (Q1 2024); net loss widened.","ACHIEVE Registrational Expansion Cohort for DYNE-101 (DM1) initiated; up to 48 patients; data H1 2026.","DELIVER Registrational Expansion Cohort for DYNE-251 (DMD) fully enrolled (32 patients); data late 2025.","New CFO (Erick Lucera), CBO (Vikram Ranade), CSO (Ranjan Batra); Oxana Beskrovnaya named CIO."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178553,"accession_number":"0001193125-25-058979","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Dyne Therapeutics appoints Erick Lucera as CFO; outgoing CFO Richard Scalzo to consult","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erick Lucera named CFO and Treasurer, effective March 31, 2025; previously CFO of Editas Medicine and AVEO Pharmaceuticals.","Lucera receives base salary $520k, bonus up to 40%, and inducement equity: 214,500 stock options + 66,100 RSUs.","Richard Scalzo steps down as SVP Finance & Treasurer same date; will provide consulting services for up to 6 months.","Scalzo's unvested equity to continue vesting during consultancy; stock option exercise period extended to 6 months post-consulting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178552,"accession_number":"0000950170-25-028369","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics reports FY2024 net loss $317.4M; advances DYNE-101 and DYNE-251 toward accelerated approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA granted Fast Track designation for DYNE-101 in DM1; registrational expansion cohort enrollment planned mid-2025.","DYNE-251 in DMD: registrational expansion cohort enrollment targeted Q1 2025; data expected late 2025.","Cash and equivalents $642.3M at Dec 31, 2024; plus $140.6M from ATM in Q1 2025; runway into H2 2026.","Q4 2024 net loss $89.5M ($0.88 per share) vs $66.6M (Q4 2023); R&D expenses $81.8M (Q4 2024).","Potential U.S. accelerated approval submissions for DYNE-101 in H1 2026 and DYNE-251 in early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178551,"accession_number":"0001193125-25-004057","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Dyne reports $642M cash, positive DYNE-101 DM1 data, H1 2026 submission path","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, and marketable securities ~$642M as of Dec 31, 2024 (unaudited).","DYNE-101 in DM1: 6.8 mg/kg Q8W dose showed robust splicing correction at 3 months and sustained functional improvements.","DYNE-101 safety: 855 doses administered, >72 patient-years follow-up; no related serious TEAEs.","Plans ~32-patient Registrational Expansion Cohort for DYNE-101 in mid-2025; U.S. accelerated approval submission targeted H1 2026.","DYNE-251 for DMD exon 51: FDA supports dystrophin as surrogate endpoint; data from 20 mg/kg cohort expected late 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195219,"accession_number":"0001193125-24-255269","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dyne upsizes ATM offering from $200M to $300M; $101.2M already sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to sell up to $300M common stock via ATM with Jefferies, up from $200M.","As of Nov 12, 2024, aggregate gross proceeds of ~$101.2M already sold under prior $200M program.","New supplement replaces prior prospectus; no further sales will be made under the old one.","Shares registered under existing shelf registration statement; legal opinion included as exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195218,"accession_number":"0000950170-24-124583","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics reports Q3 net loss $97.1M; IND cleared for DYNE-101; registrational cohort enrolling for DYNE-251","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $97.1M ($0.96 per share) vs $60.2M ($0.99) in Q3 2023; R&D expenses rose to $92.8M from $55.3M.","FDA cleared IND for DYNE-101 in DM1; Phase 1/2 ACHIEVE trial fully enrolled through 6.8 mg/kg Q8W cohort (56 participants).","New ACHIEVE data (splicing, vHOT, functional measures) expected early January 2025; pursuing accelerated approval using splicing surrogate.","Enrolling 20 mg/kg Q4W registrational cohort (n=32) in DELIVER trial for DMD exon 51; seeks accelerated approval based on dystrophin.","Cash $723.7M at Sept 30, 2024; expected to fund operations at least into H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211478,"accession_number":"0001193125-24-211534","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics initiates registrational cohorts after positive Phase 1/2 DELIVER data; leadership changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DYNE-251 (20 mg/kg Q4W) showed mean absolute dystrophin 3.71% of normal (unadjusted), >10x eteplirsen's 0.3% (cross-trial caution).","Functional improvement in NSAA, SV95C (met EMA MCID), 10-MWR, Time to Rise from Floor; 10 mg/kg cohort improved from 6 to 12 months.","Safety: favorable profile; no related SAEs except two at 40 mg/kg (resolved); >675 doses, >50 patient-years follow-up.","Leadership: CMO Wildon Farwell resigned; hired Doug Kerr as CMO, Johanna Friedl-Naderer as CCO, Lucia Celona as CHRO; CBO and COO also resigning.","Plans to update path to registration for DYNE-251 and DYNE-101 by end of 2024; ACHIEVE trial safety favorable up to 6.8 mg/kg Q8W."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211477,"accession_number":"0000950170-24-095537","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Q2 net loss $65.1M, cash $778.8M; ACHIEVE/DELIVER data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss $65.1M ($0.70/sh) vs $64.9M ($1.08/sh) in Q2 2023.","Cash, cash equivalents and marketable securities $778.8M, funded at least into H2 2026.","Completed $374.3M public offering (12.075M shares at $31.00) in May 2024.","DYNE-101 in DM1 showed splicing correction and functional improvement; DYNE-251 in DMD showed dystrophin expression exceeding eteplirsen at 6 months.","Company plans to provide registration path update for both programs by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230132,"accession_number":"0000950170-24-064700","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Dyne Therapeutics shareholders elect three Class I directors, ratify Deloitte as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Carlo Incerti, M.D. elected with 61,028,245 votes for, 8,752,856 withheld, 5,235,919 broker non-votes.","Catherine Stehman-Breen, M.D. elected with 55,026,485 votes for, 14,325,362 withheld, 5,665,173 broker non-votes.","John G. Cox elected with 69,763,860 votes for, 32,767 withheld, 5,220,393 broker non-votes.","Ratification of Deloitte & Touche as independent auditor for FY2024 passed with 74,962,217 for, 12,377 against, 42,426 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230131,"accession_number":"0001193125-24-144470","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics prices $325.5M public offering of 10.5M shares at $31.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $325.5M; net proceeds estimated at $305.4M ($351.4M if underwriters' option is fully exercised).","Underwriters include Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities; closing expected May 24, 2024.","Company granted 30-day option for underwriters to purchase an additional 1.575M shares at the same price.","Net proceeds plus existing cash expected to fund operations at least into the second half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230130,"accession_number":"0001193125-24-142232","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Dyne: DYNE-101 achieves 27% splicing correction at 3 months; DYNE-251 shows 3.22% dystrophin expression in DMD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DYNE-101 5.4 mg/kg Q8W showed 27% mean splicing correction across 22-gene panel at 3 months, all participants responded.","DYNE-101 improved myotonia (vHOT) by 4.5 sec at 3 months (5.4 mg/kg) and 4.4 sec at 12 months (1.8 mg/kg Q4W).","DYNE-251 10 mg/kg monthly achieved mean unadjusted dystrophin 3.22% (7.64% muscle-adjusted) vs 0.30% for weekly eteplirsen.","DYNE-251 showed trends in functional endpoints: NSAA, SV95C, 10-Meter Walk/Run, and Time to Rise at 6 months.","Favorable safety for both; FDA accelerated approval pathways confirmed; registration pathway update expected by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230129,"accession_number":"0000950170-24-052142","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics Q1 net loss $65.6M; cash $453.5M; clinical trials on track for H2 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $65.6M ($0.81 per share) vs $44.2M ($0.78) in Q1 2023.","Cash, equivalents and marketable securities $453.5M; expects funding through 2025.","R&D expenses $44.5M (up 19% YoY); G&A expenses $24.6M (up 211% YoY) largely due to new CEO.","John Cox appointed CEO and President in March 2024.","Phase 1/2 ACHIEVE (DM1) and DELIVER (DMD) trials progressing; additional data expected H2 2024 with registrational cohorts by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248557,"accession_number":"0001193125-24-075932","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Dyne Therapeutics appoints John Cox as President and CEO, succeeding Joshua Brumm","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Cox appointed President and CEO effective March 25, 2024; also elected Class I director.","Joshua Brumm resigns as CEO and from the Board; will serve as consultant for 12 months.","Cox receives $700K base salary, up to 60% annual bonus, and option for 679,853 shares.","Brumm gets separation: 12 months salary, COBRA, and partial equity acceleration.","Board adopts 2024 Inducement Equity Plan authorizing 900,000 shares for new hires."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248556,"accession_number":"0000950170-24-025408","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics FY2023 net loss $235.9M; positive DM1/DMD data and $345M offering extend runway to 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $66.6M ($1.09/shr) vs $38.8M ($0.74/shr) YoY; FY2023 net loss $235.9M ($3.95/shr).","Cash, equivalents and securities $123.1M at 12/31/23; Jan 2024 $345M public offering (net ~$323.9M) extends runway through 2025.","Initial ACHIEVE (DM1) data: dose-dependent splicing correction and functional myotonia improvement at 1.8 mg/kg dose.","Initial DELIVER (DMD exon 51) data: dystrophin expression exceeded eteplirsen with 24-fold lower total PMO dose; favorable safety.","Plan to report higher-dose cohort data from both trials in H2 2024; goal to initiate registrational cohorts by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248555,"accession_number":"0001193125-24-002892","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics prices $300M public offering of 17.15M shares at $17.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$300.1M from 17,150,000 shares; net proceeds ~$281.6M after discounts and expenses.","Underwriters have 30-day option for up to 2,572,500 additional shares; if exercised, net ~$323.9M.","Proceeds plus existing cash expected to fund operations through 2025.","Offering led by Morgan Stanley, J.P. Morgan, Jefferies, Stifel; expected to close January 9, 2024.","Shares sold by Dyne; no selling stockholders participating."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248554,"accession_number":"0001193125-24-002542","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Dyne Therapeutics suspends ATM offering; had raised $92.2M from prior sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company notified Jefferies it suspended and terminated the ATM prospectus dated Nov 17, 2021.","Sales agreement remains in effect; no further sales until a new prospectus is filed.","As of Jan 4, 2024, sold 7,943,148 shares for aggregate gross proceeds of $92.2 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248553,"accession_number":"0001193125-24-000991","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics announces positive initial clinical data from ACHIEVE and DELIVER trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DYNE-101 in ACHIEVE trial: 19% mean splicing correction at 3.4 mg/kg at 3 months; 3.8 sec myotonia benefit at 1.8 mg/kg at 6 months.","DYNE-251 in DELIVER trial: 0.88% mean dystrophin expression at 5 mg/kg at 6 months, exceeding eteplirsen with 24-fold lower dose.","Favorable safety profiles: no related serious adverse events; dose escalation to 6.8 mg/kg (ACHIEVE) and 40 mg/kg (DELIVER) supported.","Company plans to initiate registrational cohorts for both programs by end of 2024, with next data updates in second half of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266066,"accession_number":"0000950170-23-056122","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne reports Q3 net loss $60.2M, cash $157.8M; clinical data due Jan 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $157.8M; funding expected through 2024.","Net loss of $60.2M ($0.99 per share) vs. $41.4M ($0.80) in Q3 2022; R&D expenses rose to $55.3M from $34.7M.","ACHIEVE trial (DYNE-101 in DM1) fully enrolled through 3.4 mg/kg; dose escalation to 6.8 mg/kg enrolling; over 150 doses, no anemia or discontinuations.","DELIVER trial (DYNE-251 in DMD) fully enrolled through 10 mg/kg; dose escalation to 20 mg/kg enrolling; over 175 doses, no anemia or discontinuations.","Initial safety, splicing, dystrophin and functional data from both trials expected around J.P. Morgan Healthcare Conference in early January 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283293,"accession_number":"0000950170-23-037592","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Q2 net loss $64.9M ($1.08/sh); cash $207.7M; clinical data on track for H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $64.9M ($1.08 per share) vs $52.3M ($1.01) in Q2 2022.","R&D expenses $59.1M, up from $46.7M; G&A $7.6M vs $6.1M.","Cash and securities $207.7M as of June 30, 2023; funds operations through 2024.","Enrollment ongoing in ACHIEVE (DYNE-101, DM1) and DELIVER (DYNE-251, DMD) registrational trials; initial data expected H2 2023.","EMA granted orphan drug designation for DYNE-101 in DM1; FORCE platform CNS delivery data at ASGCT."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302724,"accession_number":"0000950170-23-024258","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Dyne Therapeutics director Lawrence Klein resigns; shareholders elect new directors and ratify auditor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Lawrence Klein resigned from Dyne Therapeutics board effective May 24, 2023, citing no disagreement with the company.","Stockholders elected Joshua Brumm, David Lubner, and Jason Rhodes as Class III directors for three-year terms.","Joshua Brumm received 35,497,922 votes for election; David Lubner received 32,530,452; Jason Rhodes received 28,522,828.","Shareholders ratified Deloitte & Touche as independent auditor for fiscal year 2023 with 44,199,721 votes for, 2,413 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302723,"accession_number":"0000950170-23-020847","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics Q1 net loss $44.2M; on track for initial trial data H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $44.2M ($0.78/share) vs $35.6M ($0.69) in Q1 2022.","Cash $238.2M at March 31; raised $24.2M via ATM after quarter; funds through 2024.","R&D expenses $37.5M, up from $28.2M YoY.","Enrollment continues in ACHIEVE (DM1) and DELIVER (DMD) trials; initial data expected H2 2023.","DYNE-251 granted orphan drug and rare pediatric disease designations by FDA in March 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322362,"accession_number":"0000950170-23-007187","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Dyne Therapeutics confirms no deposits or accounts at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Disclosure made on March 10, 2023.","Dyne confirms it does not hold any deposits at Silicon Valley Bank.","Dyne confirms it does not hold any securities at Silicon Valley Bank.","Dyne confirms it does not maintain any accounts at Silicon Valley Bank."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322361,"accession_number":"0000950170-23-005714","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics reports FY2022 net loss $168.1M; cash $256M; data readouts H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $256.0M as of Dec 31, 2022; expected to fund operations through 2024.","Net loss Q4 2022 $38.8M ($0.74/share) vs $51.8M ($1.00/share) in Q4 2021; full year net loss $168.1M ($3.23/share).","R&D expenses FY2022 $142.8M, up from $121.3M in FY2021; G&A expenses $28.2M vs $28.7M.","Enrollment continues in ACHIEVE (DYNE-101 in DM1) and DELIVER (DYNE-251 in DMD) Phase 1/2 registrational trials.","Initial data from MAD placebo-controlled portions of both trials anticipated in second half of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340411,"accession_number":"0000950170-22-021556","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics Q3 net loss $41.4M; Phase 1/2 trials for DM1 and DMD underway with data H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.4M ($0.80 per share) vs $42.6M ($0.83) in Q3 2021; cash $248.1M funds operations through 2024.","R&D expense $34.7M, G&A $7.6M; R&D slightly down YoY.","ACHIEVE trial (DYNE-101 for DM1) and DELIVER trial (DYNE-251 for DMD) both enrolling; primary endpoints safety and tolerability.","DYNE-251 granted FDA Fast Track designation in October 2022.","Data from placebo-controlled portions of both trials anticipated in second half of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357672,"accession_number":"0000950170-22-018315","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Dyne doses first patient in DYNE-251 DMD trial, initiates DYNE-101 DM1 trial, defers FSHD IND","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1/2 DELIVER trial of DYNE-251 for DMD exon 51 skipping; registrational trial targeting ~46 patients.","Initiated Phase 1/2 ACHIEVE trial for DYNE-101 in DM1; first patient expected in September 2022; target ~64 adult patients.","Deferring IND submission for DYNE-301 (FSHD) originally planned for H2 2022; update expected in 2023.","Cash runway extended through 2024 due to FSHD program deferral, based on existing cash and equivalents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357671,"accession_number":"0000950170-22-014477","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics Q2 net loss $52.3M; advances DYNE-251 and DYNE-101 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $52.3M ($1.01 per share) vs. $30.0M ($0.58) in Q2 2021; R&D expenses rose to $46.7M from $23.9M.","Cash, equivalents and marketable securities $291.8M as of June 30, 2022, expected to fund operations into H2 2024.","FDA lifted clinical hold on DYNE-251 IND for Phase 1/2 MAD trial in DMD patients amenable to exon 51 skipping; dosing expected mid-2022.","New Zealand cleared clinical trial application for DYNE-101 Phase 1/2 MAD trial in DM1; patient dosing expected mid-2022.","Presented preclinical data for DYNE-101 at ASGCT showing robust DMPK RNA knockdown in muscle models."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357670,"accession_number":"0000950170-22-012442","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2022-07-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA lifts clinical hold on Dyne's IND for DYNE-251 in Duchenne muscular dystrophy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND and lifted clinical hold for DYNE-251, targeting exon 51 skipping in DMD.","Dyne expects to begin dosing patients in a Phase 1/2 trial in mid-2022.","Trial will enroll 30–50 males ages 4–16, both ambulant and non-ambulant.","Endpoints include safety, dystrophin expression by Western blot, PK/PD, and muscle function.","Company will release trial design details and data timing upon first dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376276,"accession_number":"0000950170-22-011171","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Dyne Therapeutics shareholders elect Hurwitz and Kersten to board, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Edward Hurwitz elected as Class II director: 20,392,039 for, 7,406,127 withheld, 3,170,612 broker non-votes.","Dirk Kersten elected as Class II director: 20,066,236 for, 7,731,930 withheld, 3,170,612 broker non-votes.","Ratified Deloitte & Touche as auditor for FY2022: 30,967,416 for, 362 against, 1,000 abstain.","Annual meeting held June 3, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376275,"accession_number":"0000950170-22-006866","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2022-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics Reports Q1 2022 Net Loss of $35.6M and Provides Clinical Milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q1 2022 was $35.6 million ($0.69 per share) vs. $25.0 million in Q1 2021.","Cash, cash equivalents and marketable securities totaled $323.2 million as of March 31, 2022.","R&D expenses were $28.2 million in Q1 2022, up from $18.6 million in Q1 2021.","Company plans to submit IND response for DYNE-251 in DMD and regulatory filings for DYNE-101 in DM1 in Q2 2022.","Initiation of multiple ascending dose clinical trials for DYNE-251 and DYNE-101 anticipated in mid-2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394633,"accession_number":"0000950170-22-003293","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics reports FY2021 net loss $149.3M; cash to H2 2024; pipeline milestones outlined","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $149.3M for 2021 ($2.93/share) vs $59.4M in 2020; R&D spend $121.3M.","Cash, equivalents and securities $376.6M at Dec 31, 2021; cash runway into second half 2024.","FDA response for DYNE-251 IND in DMD expected Q2 2022; patient dosing in Phase 1/2 planned mid-2022.","Regulatory filings for DYNE-101 in DM1 in multiple countries planned Q2 2022 with mid-2022 trial start.","IND for DYNE-301 in FSHD expected in second half of 2022; board appointment of Carlo Incerti, M.D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-10T23:59:59+00:00|394633"}